But there are no hard facts, and a Ligand obligation clouds future licensing economics.

Now in Bristol’s hands, BMS-986442 is set to deliver its first clinical data.

The FDA throws out the company’s second attempt at an accelerated approval.

A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.

But efficacy still needs to go up, as several groups try to combine PD-1 and CTLA-4 using differing approaches.

Disclosure of BMS-986442’s second target antigen endorses Agenus, and is highly relevant for GSK and Compugen too.

Seagen/Genmab’s confirmatory cervical cancer trial is toplined positive, putting up a fresh roadblock for Iovance’s accelerated filing plans.